Health TrialsbyHealthPanel

Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix

ConditionsCervical Large Cell Neuroendocrine CarcinomaCervical Neuroendocrine CarcinomaCervical Small Cell CarcinomaCervical Undifferentiated CarcinomaStage I Cervical Cancer AJCC v8Stage IA Cervical Cancer AJCC v8Stage IA1 Cervical Cancer AJCC v8Stage IA2 Cervical Cancer AJCC v8Stage IB Cervical Cancer AJCC v8Stage IB1 Cervical Cancer AJCC v8Stage IB2 Cervical Cancer AJCC v8Stage II Cervical Cancer AJCC v8Stage IIA Cervical Cancer AJCC v8Stage IIA1 Cervical Cancer AJCC v8Stage IIA2 Cervical Cancer AJCC v8Stage IIB Cervical Cancer AJCC v8Stage III Cervical Cancer AJCC v8Stage IIIA Cervical Cancer AJCC v8Stage IIIB Cervical Cancer AJCC v8Stage IV Cervical Cancer AJCC v8Stage IVA Cervical Cancer AJCC v8Stage IVB Cervical Cancer AJCC v8
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorM.D. Anderson Cancer Center

About this trial

This study collects information and data on patients with neuroendocrine cervical cancer. Information from this study may be used to better understand the correlation between clinical data, such as patient characteristics, treatment, and disease outcomes, and overall patient outcomes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Small cell neuroendocrine carcinoma

Large cell neuroendocrine carcinoma

Undifferentiated high-grade neuroendocrine carcinoma

Patients may be in any stage of treatment, surveillance or recurrence at the time of initial participation in the study

Disqualifiers

Patients with other histologic subtypes of NEC of the cervix including typical and atypical carcinoid tumors

Trial population

Patients with neuroendocrine cervical cancer

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

  • Follow-Up

    Other intervention

    Receive follow up

  • Medical Chart Review

    Other intervention

    Review of medical records

Treatment groups

750 Participants
are divided into 1 treatment group
Group A: Observational (medical chart review)2 interventions

Trial outcomes

Primary outcomes

1

Disease characterization data

Information collected from retrospective and prospective review of medical records.

Time frame
through study completion, an average of 1 year
2

Patient treatment data

Information collected from retrospective and prospective review of medical records.

Time frame
through study completion, an average of 1 year
3

Patient outcome data

Information collected from retrospective and prospective review of medical records.

Time frame
through study completion, an average of 1 year

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

M.D. Anderson Cancer Center

Lead sponsor

Source ClinicalTrials.gov
Apply now